Therapeutic effect of TAS-102 (A) in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy by the Kohne model (Km).

被引：1
|
作者：
Nishina, Tomohiro
Yoshino, Takayuki
Mizunuma, Nobuyuki
Yamazaki, Kentaro
Komatsu, Yoshito
Baba, Hideo
Tsuji, Akihito
Yamaguchi, Kensei
Muro, Kei
Ohtsu, Atsushi
机构：
[1] Natl Hosp Org, Shikoku Canc Ctr, Shikoku, Ehime, Japan
[2] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[3] Canc Inst Hosp, Dept Med Oncol, Tokyo, Japan
[4] Shizuoka Canc Ctr, Shizuoka, Japan
[5] Hokkaido Univ Hosp, Dept Canc Ctr, Sapporo, Hokkaido, Japan
[6] Kumamoto Univ Hosp, Kumamoto, Japan
[7] Kochi Hlth Sci Ctr, Kochi, Japan
[8] Saitama Canc Ctr, Saitama, Japan
[9] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.650
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
650
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Factors associated with efficacy of TAS-102 in patients with refractory metastatic colorectal cancer (mCRC).
    Grell, Peter
    Dvorak, Josef
    Vocka, Michal
    John, Stanislav
    Tuskova, Helena
    Buchler, Tomas
    Petruzelka, Lubos B.
    Vyzula, Rostislav
    Obermannova, Radka
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [2] A phase I dose-escalation study of TAS-102 in patients (pts) with refractory metastatic colorectal cancer (mCRC).
    Patel, Manish R.
    Bendell, Johanna C.
    Mayer, Robert J.
    Benedetti, Fabio M.
    Rosen, Lee S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] TAS-102 for metastatic refractory colorectal cancer
    Cleghorn, Sean
    LANCET ONCOLOGY, 2015, 16 (07): : E314 - E314
  • [4] TAS-102 in patients with metastatic colorectal cancer refractory to standard therapies including regorafenib
    Kito, Yosuke
    Hamauchi, Satoshi
    Yamazaki, Kentaro
    Komori, Azusa
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Mori, Keita
    Muro, Kei
    Yasui, Hirofumi
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies
    Sueda, Toshinori
    Sakai, Daisuke
    Kudo, Toshihiro
    Sugiura, Takashi
    Takahashi, Hidekazu
    Haraguchi, Naotsugu
    Nishimura, Junichi
    Hata, Taishi
    Hayashi, Taro
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Masaki
    Satoh, Taroh
    ANTICANCER RESEARCH, 2016, 36 (08) : 4299 - 4306
  • [6] Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
    Mayer, Robert J.
    Van Cutsem, Eric
    Falcone, Alfredo
    Yoshino, Takayuki
    Garcia-Carbonero, Rocio
    Mizunuma, Nobuyuki
    Yamazaki, Kentaro
    Shimada, Yasuhiro
    Tabernero, Josep
    Komatsu, Yoshito
    Sobrero, Alberto
    Boucher, Eveline
    Peeters, Marc
    Tran, Ben
    Lenz, Heinz-Josef
    Zaniboni, Alberto
    Hochster, Howard
    Cleary, James M.
    Prenen, Hans
    Benedetti, Fabio
    Mizuguchi, Hirokazu
    Makris, Lukas
    Ito, Masanobu
    Ohtsu, Atsushi
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (20): : 1909 - 1919
  • [7] A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study
    Yamazaki, K.
    Yasui, H.
    Yamaguchi, K.
    Kagawa, Y.
    Kuboki, Y.
    Yoshino, T.
    Gamoh, M.
    Komatsu, Y.
    Satake, H.
    Goto, M.
    Tanioka, H.
    Oki, E.
    Kotaka, M.
    Makiyama, A.
    Denda, T.
    Soeda, J.
    Shibya, K.
    Iwata, M.
    Oba, K.
    Kato, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] Sidedness of the primary tumor on the effect of TAS-102 for refractory metastatic colorectal cancer
    Ueda, S.
    Tsuboguchi, Y.
    Nakatani, Y.
    Tsuya, A.
    Nishina, S-I.
    Akiyoshi, K.
    Okazaki, S.
    Tokunaga, S.
    Daga, H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] TAS-102 in metastatic colorectal cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2018, 19 (01): : E18 - E18
  • [10] A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).
    Cecchini, Michael
    Kortmansky, Jeremy S.
    Lacy, Jill
    Fischbach, Neal A.
    Thumar, Jaykumar Ranchodbhai
    Sabbath, Kert D.
    Gomez, Christina M.
    Sporn, Jonathan
    Stein, Stacey
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345